Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. India
  4. Bombay Stock Exchange
  5. Piramal Enterprises Limited
  6. News
  7. Summary
    500302   INE140A01024

PIRAMAL ENTERPRISES LIMITED

(500302)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Piramal Enterprises Limited : Announces Consolidated Results for Q1 FY2022

08/09/2021 | 10:34am EST

Mumbai, India - Piramal Enterprises Limited ('PEL', NSE: PEL, BSE: 500302) announced its consolidated results for the First Quarter (Q1) FY2022 ended 30th June 2021.

Ajay Piramal, Chairman, Piramal Enterprises Ltd. said, 'Despite the impact of the second wave of Covid-19, we have delivered resilient performance during the quarter with Revenues at INR 2,909 Crores, Net Profit YoY growth by 8% to INR 534 Crores. We continue to maintain a strong balance sheet, with net debt-to-equity ratio at 0.8x. In Financial Services, our resolution plan for DHFL's acquisition received NCLT-approval in June-2021. We are on track with the Monitoring Committee mandate for completion of this transaction within 90 days from NCLT approval. After successfully going through the recent consolidation phase, we are now transitioning from a wholesale-led to a well-diversified Financial Services business. The transition augmented by the DHFL acquisition will not only bring quantum growth in our loan book but also create a large India-wide platform that will enable us to deliver sustained growth and profitability in the years to come. Our Pharma business continues to deliver robust performance during the quarter, with 31% YoY revenue growth, indicating the strength of our business model. In addition, post the capital raise from the Carlyle Group, we have accelerated on our two-pronged strategic growth trajectory though investments in both organic and inorganic initiatives. While we remain cautiously optimistic for FY22, we see a strong runway for growth across both our businesses. Our immediate focus will be to effectively integrate DHFL with our Financial Services organization. Pursuant to which, we will be better positioned to announce our plan to create two separate listed entities in Financial Services and Pharma.

About Piramal Enterprises Ltd: Piramal Enterprises Limited (PEL) is one of the large companies in India, with a presence in Financial Services and Pharmaceuticals. PEL's consolidated revenues were US$1.7 Billion in FY 2021, with ~37% of revenues generated from outside India. In Financial Services, the Company offers a wide range of financial products and solutions, with presence across both retail and wholesale financing. Within retail lending, through its multi-product platform, the Company offers home loans, loans for small businesses and loans for working capital to customers in affordable housing and mass affluent segments across Tier I, II and III cities. Within wholesale lending, the business provides financing to real estate developers, as well as corporate clients. The Company has also formed strategic partnerships with leading financial institutions such as CPPIB, APG and Ivanhoe Cambridge, etc. across various investment platforms. Piramal Alternatives, the fund management business, provides customised financing solutions to high quality corporates through - 'Piramal Credit Fund', a performing, sector-agnostic credit fund with capital commitment from CDPQ; and 'IndiaRF', a distressed asset investing platform with Bain Capital Credit, which invests in equity and/or debt across non-real estate sectors. PEL also has equity investments in the Shriram Group, a leading financial conglomerate in India. In Pharma, the Company has a differentiated business model that is diversified across three segments: Contract Development and Manufacturing Organization (CDMO), Complex Hospital Generics (CHG) and India Consumer Healthcare. Through end-to-end manufacturing capabilities across 15 global facilities and a large global distribution network spanning over 100 countries, PEL sells a portfolio of niche differentiated pharma products and provides an entire pool of pharma services. CDMO business offers integrated solutions across the drug lifecycle - ranging from discovery clinical development to commercial manufacturing of Active Pharmaceutical Ingredients (APIs) and Formulations. The Complex Hospital Generics business markets niche inhalation anaesthesia, injectable anaesthesia, intrathecal spasticity and pain management and select antibiotics. PEL's Consumer Healthcare business is among the leading players in India in the self-care space, with established brands in the Indian consumer healthcare market. The Pharma Business has a joint venture with Allergan, a leader in ophthalmology in the Indian formulations market. In October 2020, the company raised fresh equity from The Carlyle Group for a 20% stake in Piramal Pharma.

Contact:

Media

Dimple Kapur

Corporate Communications

E: Dimple.Kapur@piramal.com

Investors

Hitesh Dhaddha

Investor Relations

E: investor.relations@piramal.com

(C) 2021 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
PIRAMAL ENTERPRISES LIMITED -6.74% 2472.2 End-of-day quote.72.93%
THE CARLYLE GROUP INC. -4.28% 54.75 Delayed Quote.74.14%
All news about PIRAMAL ENTERPRISES LIMITED
11/26India central bank sidesteps proposal on corporate ownership of banks
RE
11/11Banks, auto stocks drag Indian shares as inflation fears weigh
RE
11/11Piramal Enterprises Limited Reports Earnings Results for the Second Quarter and Six Mon..
CI
11/11Piramal Enterprises Limited Announces Consolidated Results for Q2 FY2022
PU
10/08PIRAMAL ENTERPRISES : Announces Demerger and Simplification of Corporate Structure, To Cre..
AQ
10/07PIRAMAL ENTERPRISES : to Demerge Pharma, Financial Services Business in Restructuring
MT
10/07Piramal Group to Demerge Financial, Pharma Biz into Separate Listed Entities
CI
10/07OIL AND NATURAL GAS : Indian shares end higher as auto stocks drive gains
RE
10/07India's Piramal Enterprises to demerge and list pharma business
RE
10/07PIRAMAL ENTERPRISES : Announces Demerger and Simplification of Corporate Structure; To Cre..
PU
More news
Financials
Sales 2022 144 B 1 925 M 1 925 M
Net income 2022 25 603 M 341 M 341 M
Net Debt 2022 479 B 6 381 M 6 381 M
P/E ratio 2022 23,2x
Yield 2022 1,33%
Capitalization 590 B 7 862 M 7 867 M
EV / Sales 2022 7,40x
EV / Sales 2023 6,11x
Nbr of Employees 6 638
Free-Float 53,2%
Chart PIRAMAL ENTERPRISES LIMITED
Duration : Period :
Piramal Enterprises Limited Technical Analysis Chart | 500302 | INE140A01024 | MarketScreener
Technical analysis trends PIRAMAL ENTERPRISES LIMITED
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 2 472,20 INR
Average target price 3 102,40 INR
Spread / Average Target 25,5%
EPS Revisions
Managers and Directors
Peter D. DeYoung Chief Executive Officer
Bector Vikram Co-President & Chief Human Resources Officer
Vivek Valsaraj Co-President & Chief Financial Officer
Rajesh Ratanlal Laddha Group Chief Financial Officer & Executive Director
Ajay Gopikisan Piramal Chairman
Sector and Competitors
1st jan.Capi. (M$)
PIRAMAL ENTERPRISES LIMITED72.93%7 862
BAJAJ FINANCE LIMITED28.47%54 535
SYNCHRONY FINANCIAL37.37%26 093
ORIX CORPORATION48.69%24 905
MUTHOOT FINANCE LIMITED19.01%7 704
ONEMAIN HOLDINGS, INC.3.95%6 482